NeoVentures is pleased to announce that a long term project with a Fortune 500 company regarding the development of an aptamer that binds to a transmembrane receptor is currently under review by the FDA. This multi-year project was contracted to NeoVentures because of our expertise with the selection of aptamers that either induce endocytosis by binding to transmembrane receptors on specific target cells, or do not induce endocytosis and thus have the capacity to block cellular entry of infectious moieties. NeoVentures also provided extensive transcriptomics analysis of the effect of the aptamer on gene expression in targeted cells, and provided support in the development of the FDA submission.
This announcement concerns only one of several projects that NeoVentures has successfully delivered in this area. We are currently working with our partners to move other aptamers that we have developed for transmembrane receptors to commercial realization as vectors for drug delivery or inhibitors of infection.
To learn more about aptamer development capacity please contact us for a free consultation.

Dr. Gregory Penner academic training was a blend of very practical plant breeding theory combined with molecular biology. He has used this blend of biology and mathematics to first develop and lead a cereal biotechnology research team with the government of Canada and subsequently as a global research leader with Monsanto Inc. He has been a thought leader in aptamer development globally for the last twenty years as CEO and President of NeoVentures. He has led this company to financial stability without outside investment with an integrated approach to aptamer discovery and commercialization. In 2015, he co- founded a second company, NeoNeuro in Paris France, focused on an innovative approach to identify Aptamarkers for complex diseases.
Connect with Dr. Penner on LinkedIn or for company updates, follow NeoVentures.